Bresci G, Carrai M, Venturini G, Gambardella L
U.S.L. n. 12, Pisa, Divisione di Gastroenterologia.
Minerva Dietol Gastroenterol. 1990 Jan-Mar;36(1):31-3.
The aim of the study was to compare the efficacy and side-effects of 5-ASA and SASP in the treatment of active ulcerative colitis. An improvement was seen in 71.4% (5-ASA) and 70.3% (SASP) but there were no complete remissions. The incidence of improvements was only 36.3% (5-ASA) and 37.5% (SASP) in pancolitis. The side-effects appeared in 14.2% (5-ASA) and 21% (SASP).
该研究的目的是比较5-氨基水杨酸(5-ASA)和柳氮磺胺吡啶(SASP)治疗活动期溃疡性结肠炎的疗效和副作用。5-ASA组有71.4%的患者病情改善,SASP组为70.3%,但均无完全缓解。全结肠炎患者中,5-ASA组病情改善率仅为36.3%,SASP组为37.5%。5-ASA组副作用发生率为14.2%,SASP组为21%。